Polaryx Therapeutics, Inc. (PLYX)
| Market Cap | 144.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.21M |
| Shares Out | 47.34M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279,292 |
| Open | 3.250 |
| Previous Close | 3.190 |
| Day's Range | 3.010 - 3.410 |
| 52-Week Range | 2.201 - 48.910 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 10.00 (+227.87%) |
| Earnings Date | n/a |
About PLYX
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PLYX stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal s...
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics Inc. (NASDAQ: PLYX) shares are up on Tuesday as the company has made significant strides in advancing its clinical programs.
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysos...
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal s...
Polaryx Therapeutics Welcomes New Members of the Board of Directors
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel,...
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug ca...
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization o...
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization o...
Polaryx Therapeutics Seeks Direct Listing For Shareholders
Polaryx Therapeutics is pursuing a direct listing with no proceeds to the company and no new institutional investors involved. PLYX is a clinical-stage biopharma targeting lysosomal storage disorders,...